What is a stock summary page? Click here for an overview.
Business Description
Cara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1407551092
Description
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.09 | |||||
| Equity-to-Asset | -0.11 | |||||
| Debt-to-Equity | -0.74 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -27.34 | |||||
| Beneish M-Score | -1.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -34 | |||||
| 3-Year EBITDA Growth Rate | 13 | |||||
| 3-Year EPS without NRI Growth Rate | 15.2 | |||||
| 3-Year FCF Growth Rate | 1.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.92 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.11 | |||||
| 9-Day RSI | 79.34 | |||||
| 14-Day RSI | 73.16 | |||||
| 6-1 Month Momentum % | 91.36 | |||||
| 12-1 Month Momentum % | -49.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.03 | |||||
| Quick Ratio | 10.81 | |||||
| Cash Ratio | 9.54 | |||||
| Days Inventory | 1028 | |||||
| Days Sales Outstanding | 58.14 | |||||
| Days Payable | 3213.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -9.22 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.31 | |||||
| Operating Margin % | -740.06 | |||||
| Net Margin % | -992.95 | |||||
| FCF Margin % | -866.46 | |||||
| ROE % | -374.56 | |||||
| ROA % | -92.37 | |||||
| ROIC % | -551.28 | |||||
| 3-Year ROIIC % | -46.9 | |||||
| ROC (Joel Greenblatt) % | -907.37 | |||||
| ROCE % | -99.67 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.07 | |||||
| EV-to-EBIT | 0.25 | |||||
| EV-to-EBITDA | 0.25 | |||||
| EV-to-Forward-EBITDA | -0.04 | |||||
| EV-to-Revenue | -2.23 | |||||
| EV-to-Forward-Revenue | 0.06 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-GF-Value | 0.84 | |||||
| Price-to-Median-PS-Value | 0.1 | |||||
| Earnings Yield (Greenblatt) % | 400 | |||||
| FCF Yield % | -282.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cara Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.578 | ||
| EPS (TTM) (€) | -14.446 | ||
| Beta | 1.26 | ||
| 3-Year Sharpe Ratio | -0.83 | ||
| 3-Year Sortino Ratio | -1.08 | ||
| Volatility % | 99.81 | ||
| 14-Day RSI | 73.16 | ||
| 14-Day ATR (€) | 0.002043 | ||
| 20-Day SMA (€) | 4.836 | ||
| 12-1 Month Momentum % | -49.5 | ||
| 52-Week Range (€) | 2.2008 - 9.198 | ||
| Shares Outstanding (Mil) | 4.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cara Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cara Therapeutics Inc Frequently Asked Questions
What is Cara Therapeutics Inc(FRA:69C0)'s stock price today?
The current price of FRA:69C0 is €4.84. The 52 week high of FRA:69C0 is €9.20 and 52 week low is €2.20.
When is next earnings date of Cara Therapeutics Inc(FRA:69C0)?
The next earnings date of Cara Therapeutics Inc(FRA:69C0) is 2025-05-13 Est..
Does Cara Therapeutics Inc(FRA:69C0) pay dividends? If so, how much?
Cara Therapeutics Inc(FRA:69C0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers